Pharma Focus Asia

China's Fosun Pharma to buy smaller stake in Indian pharma firm

Monday, September 18, 2017

Shanghai Fosun Pharmaceutical Group has agreed to cut the size of the stake it will buy in India’s Gland Pharma to 74 percent, the Chinese drugmaker said on Sunday.

It said Gland Pharma’s founding family wanted to retain a higher stake in the Indian firm because of its good performance.

Fosun had previously been targetting an 86 percent stake valued at about $1.26 billion. It said in a statement to the stock exchange that the board had approved the new plan, which would involve investment of no more than $1.09 billion.

The deal had earlier faced some concerns in India, a source has told Reuters.

Under the new terms, Fosun Pharma said it would spend no more than $25 million for the Indian firm’s Enoxaparin prototype sales in the United States, when it gets approval there, cutting the previously proposed amount by half.

The firm has also delayed the closing date for the deal to Oct. 3 from Sept. 26.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024